EU Approves Another Biosimilar of AbbVie’s Humira

The EU approved Mylan’s Hulio (adalimumab), the fifth biosimilar for AbbVie’s Humira, for treatment of rheumatoid arthritis.

Adalimumab given in combination with methotrexate has been shown to reduce the rate of progression of joint damage and to improve physical function.

Hulio’s approval marks Mylan’s fourth product in the field of biosimilars and complex generics. The company anticipates a European launch on or after Oct. 16.